Neurocrine Biosciences is reportedly close to finalizing a deal to acquire Soleno Therapeutics. The potential acquisition is valued at over $2.5 billion, according to reports from the Financial Times.

Goldman Sachs anticipates double-digit earnings growth for Teva Pharmaceutical Industries through 2026, while Edison International posts strong 2025 results and sets 2026–2027 EPS targets. Needham is bullish on Neurocrine Biosciences' pipeline, expecting growth from Crenessity and Ingrezza by 2026.

Neurocrine Biosciences has mapped out its execution plans for 2026 and a 'data-rich' 2027, with its drug Ingrezza projected to guide $2.7B–$2.8B.

Truist has reduced its price target for Neurocrine Biosciences, Inc. (NBIX) following the company's update on its 2026 financial outlook.